LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 111

Search options

  1. Book ; Online ; Thesis: Charakterisierung von Zone 1-Sternzellen in der murinen Leber

    Fischer, Julian [Verfasser] / Friebe, Andreas [Gutachter] / Gallant, Peter [Gutachter]

    2024  

    Author's details Julian Fischer ; Gutachter: Andreas Friebe, Peter Gallant
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Universität Würzburg
    Publishing place Würzburg
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  2. Article ; Online: NO-sensitive guanylyl cyclase in the lung.

    Friebe, Andreas / Englert, Nils

    British journal of pharmacology

    2021  Volume 179, Issue 11, Page(s) 2328–2343

    Abstract: In the late 1960s, several labatories identified guanylyl cyclase (GC) as the cGMP-producing enzyme. Subsequently, two different types of GC were described that differed in their cellular localization. Primarily found in the cytosol, nitric oxide (NO)- ... ...

    Abstract In the late 1960s, several labatories identified guanylyl cyclase (GC) as the cGMP-producing enzyme. Subsequently, two different types of GC were described that differed in their cellular localization. Primarily found in the cytosol, nitric oxide (NO)-sensitive guanylyl cyclase (NO-GC) acts as receptor for the signalling molecule NO, in contrast the membrane-bound isoenzyme is activated by natriuretic peptides. The lung compared with other tissues exhibits the highest expression of NO-GC. The enzyme has been purified from lung for biochemical analysis. Although expressed in smooth muscle cells (SMCs) and in pericytes, the function of NO-GC in lung, especially in pericytes, is still not fully elucidated. However, pharmacological compounds that target NO-GC are available and have been implemented for the therapy of pulmonary arterial hypertension. In addition, NO-GC has been suggested as drug target for the therapy of asthma, acute respiratory distress syndrome and pulmonary fibrosis. LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc.
    MeSH term(s) Cyclic GMP/metabolism ; Guanylate Cyclase/metabolism ; Lung/metabolism ; Nitric Oxide/metabolism ; Soluble Guanylyl Cyclase
    Chemical Substances Nitric Oxide (31C4KY9ESH) ; Guanylate Cyclase (EC 4.6.1.2) ; Soluble Guanylyl Cyclase (EC 4.6.1.2) ; Cyclic GMP (H2D2X058MU)
    Language English
    Publishing date 2021-01-15
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 80081-8
    ISSN 1476-5381 ; 0007-1188
    ISSN (online) 1476-5381
    ISSN 0007-1188
    DOI 10.1111/bph.15345
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book ; Online ; Thesis: Die Rolle der NO-sensitiven Guanylyl-Cyclase in der Lungenfibrose der Maus

    Englert, Nils [Verfasser] / Friebe, Andreas [Gutachter] / Butt, Elke [Gutachter] / Metzger, Marco [Gutachter]

    2024  

    Author's details Nils Englert ; Gutachter: Andreas Friebe, Elke Butt, Marco Metzger
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Universität Würzburg
    Publishing place Würzburg
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  4. Article ; Online: Anti-Fibrotic and Anti-Inflammatory Role of NO-Sensitive Guanylyl Cyclase in Murine Lung.

    Englert, Nils / Burkard, Philipp / Aue, Annemarie / Rosenwald, Andreas / Nieswandt, Bernhard / Friebe, Andreas

    International journal of molecular sciences

    2023  Volume 24, Issue 14

    Abstract: Pulmonary fibrosis is a chronic and progressive disease with limited therapeutic options. Nitric oxide (NO) is suggested to reduce the progression of pulmonary fibrosis via NO-sensitive guanylyl cyclase (NO-GC). The exact effects of NO-GC during ... ...

    Abstract Pulmonary fibrosis is a chronic and progressive disease with limited therapeutic options. Nitric oxide (NO) is suggested to reduce the progression of pulmonary fibrosis via NO-sensitive guanylyl cyclase (NO-GC). The exact effects of NO-GC during pulmonary fibrosis are still elusive. Here, we used a NO-GC knockout mouse (GCKO) and examined fibrosis and inflammation after bleomycin treatment. Compared to wildtype (WT), GCKO mice showed an increased fibrotic reaction, as myofibroblast occurrence (
    MeSH term(s) Mice ; Animals ; Soluble Guanylyl Cyclase/metabolism ; Pulmonary Fibrosis/drug therapy ; Pulmonary Fibrosis/pathology ; Lung/pathology ; Mice, Knockout ; Bronchoalveolar Lavage Fluid ; Transforming Growth Factor beta/metabolism ; Anti-Inflammatory Agents/therapeutic use ; Bleomycin/pharmacology ; Mice, Inbred C57BL
    Chemical Substances Soluble Guanylyl Cyclase (EC 4.6.1.2) ; Transforming Growth Factor beta ; Anti-Inflammatory Agents ; Bleomycin (11056-06-7)
    Language English
    Publishing date 2023-07-19
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms241411661
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report.

    Friebe, Andreas / Kraehling, Jan R / Russwurm, Michael / Sandner, Peter / Schmidtko, Achim

    Naunyn-Schmiedeberg's archives of pharmacology

    2023  Volume 396, Issue 8, Page(s) 1669–1686

    Abstract: Increasing cGMP is a unique therapeutic principle, and drugs inhibiting cGMP-degrading enzymes or stimulating cGMP production are approved for the treatment of various diseases such as erectile dysfunction, coronary artery disease, pulmonary hypertension, ...

    Abstract Increasing cGMP is a unique therapeutic principle, and drugs inhibiting cGMP-degrading enzymes or stimulating cGMP production are approved for the treatment of various diseases such as erectile dysfunction, coronary artery disease, pulmonary hypertension, chronic heart failure, irritable bowel syndrome, or achondroplasia. In addition, cGMP-increasing therapies are preclinically profiled or in clinical development for quite a broad set of additional indications, e.g., neurodegenerative diseases or different forms of dementias, bone formation disorders, underlining the pivotal role of cGMP signaling pathways. The fundamental understanding of the signaling mediated by nitric oxide-sensitive (soluble) guanylyl cyclase and membrane-associated receptor (particulate) guanylyl cyclase at the molecular and cellular levels, as well as in vivo, especially in disease models, is a key prerequisite to fully exploit treatment opportunities and potential risks that could be associated with an excessive increase in cGMP. Furthermore, human genetic data and the clinical effects of cGMP-increasing drugs allow back-translation into basic research to further learn about signaling and treatment opportunities. The biannual international cGMP conference, launched nearly 20 years ago, brings all these aspects together as an established and important forum for all topics from basic science to clinical research and pivotal clinical trials. This review summarizes the contributions to the "10th cGMP Conference on cGMP Generators, Effectors and Therapeutic Implications," which was held in Augsburg in 2022 but will also provide an overview of recent key achievements and activities in the field of cGMP research.
    MeSH term(s) Male ; Humans ; Guanylate Cyclase/metabolism ; Soluble Guanylyl Cyclase/metabolism ; Cyclic GMP/metabolism ; Signal Transduction ; Research ; Nitric Oxide/metabolism
    Chemical Substances Guanylate Cyclase (EC 4.6.1.2) ; Soluble Guanylyl Cyclase (EC 4.6.1.2) ; Cyclic GMP (H2D2X058MU) ; Nitric Oxide (31C4KY9ESH)
    Language English
    Publishing date 2023-04-20
    Publishing country Germany
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 121471-8
    ISSN 1432-1912 ; 0028-1298
    ISSN (online) 1432-1912
    ISSN 0028-1298
    DOI 10.1007/s00210-023-02484-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book ; Thesis: Die Einstellung zur psychosozialen Medizin im Kursus der Medizinischen Psychologie

    Friebe, Andreas

    empirische Untersuchung, durchgeführt an Freiburger Medizinstudenten im 3. vorklinischen Semester

    1988  

    Author's details vorgelegt von Andreas Friebe
    Size 2 Mikrofiches : 48x
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Freiburg (Breisgau), Univ., Diss., 1988
    Note Mikroreprod. e. Ms. 279, [109] Bl.: graph. Darst.
    HBZ-ID HT003763500
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  7. Article ; Online: NO-sensitive guanylyl cyclase discriminates pericyte-derived interstitial from intra-alveolar myofibroblasts in murine pulmonary fibrosis.

    Aue, Annemarie / Englert, Nils / Harrer, Leon / Schwiering, Fabian / Gaab, Annika / König, Peter / Adams, Ralf / Schmidtko, Achim / Friebe, Andreas / Groneberg, Dieter

    Respiratory research

    2023  Volume 24, Issue 1, Page(s) 167

    Abstract: Background: The origin of αSMA-positive myofibroblasts, key players within organ fibrosis, is still not fully elucidated. Pericytes have been discussed as myofibroblast progenitors in several organs including the lung.: Methods: Using tamoxifen- ... ...

    Abstract Background: The origin of αSMA-positive myofibroblasts, key players within organ fibrosis, is still not fully elucidated. Pericytes have been discussed as myofibroblast progenitors in several organs including the lung.
    Methods: Using tamoxifen-inducible PDGFRβ-tdTomato mice (PDGFRβ-CreER
    Results: Lineage tracing combined with immunofluorescence for nitric oxide-sensitive guanylyl cyclase (NO-GC) as marker for PDGFRβ-positive pericytes allows differentiating two types of αSMA-expressing myofibroblasts in murine pulmonary fibrosis: (1) interstitial myofibroblasts that localize in the alveolar wall, derive from PDGFRβ
    Conclusion: In summary, αSMA/PDGFRβ-positive myofibroblasts should not be addressed as a homogeneous target cell type within pulmonary fibrosis.
    MeSH term(s) Mice ; Animals ; Pulmonary Fibrosis/metabolism ; Pericytes/metabolism ; Myofibroblasts/metabolism ; Guanylate Cyclase/metabolism ; Fibrosis ; Collagen/metabolism
    Chemical Substances Guanylate Cyclase (EC 4.6.1.2) ; Collagen (9007-34-5)
    Language English
    Publishing date 2023-06-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041675-1
    ISSN 1465-993X ; 1465-993X
    ISSN (online) 1465-993X
    ISSN 1465-993X
    DOI 10.1186/s12931-023-02479-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Role of the NO-GC/cGMP signaling pathway in platelet biomechanics.

    Balmes, Aylin / Rodríguez, Johanna G / Seifert, Jan / Pinto-Quintero, Daniel / Khawaja, Akif A / Boffito, Marta / Frye, Maike / Friebe, Andreas / Emerson, Michael / Seta, Francesca / Feil, Robert / Feil, Susanne / Schäffer, Tilman E

    Platelets

    2024  Volume 35, Issue 1, Page(s) 2313359

    Abstract: Cyclic guanosine monophosphate (cGMP) is a second messenger produced by the NO-sensitive guanylyl cyclase (NO-GC). The NO-GC/cGMP pathway in platelets has been extensively studied. However, its role in regulating the biomechanical properties of platelets ...

    Abstract Cyclic guanosine monophosphate (cGMP) is a second messenger produced by the NO-sensitive guanylyl cyclase (NO-GC). The NO-GC/cGMP pathway in platelets has been extensively studied. However, its role in regulating the biomechanical properties of platelets has not yet been addressed and remains unknown. We therefore investigated the stiffness of living platelets after treatment with the NO-GC stimulator riociguat or the NO-GC activator cinaciguat using scanning ion conductance microscopy (SICM). Stimulation of human and murine platelets with cGMP-modulating drugs decreased cellular stiffness and downregulated P-selectin, a marker for platelet activation. We also quantified changes in platelet shape using deep learning-based platelet morphometry, finding that platelets become more circular upon treatment with cGMP-modulating drugs. To test for clinical applicability of NO-GC stimulators in the context of increased thrombogenicity risk, we investigated the effect of riociguat on platelets from human immunodeficiency virus (HIV)-positive patients taking abacavir sulfate (ABC)-containing regimens. Our results corroborate a functional role of the NO-GC/cGMP pathway in platelet biomechanics, indicating that biomechanical properties such as stiffness or shape could be used as novel biomarkers in clinical research.
    MeSH term(s) Humans ; Mice ; Animals ; Biomechanical Phenomena ; Blood Platelets/metabolism ; Signal Transduction ; Guanylate Cyclase/metabolism ; Guanylate Cyclase/pharmacology ; Platelet Activation ; Cyclic GMP/metabolism ; Cyclic GMP/pharmacology ; Nitric Oxide/metabolism ; Platelet Aggregation
    Chemical Substances Guanylate Cyclase (EC 4.6.1.2) ; Cyclic GMP (H2D2X058MU) ; Nitric Oxide (31C4KY9ESH)
    Language English
    Publishing date 2024-02-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 1034283-7
    ISSN 1369-1635 ; 0953-7104
    ISSN (online) 1369-1635
    ISSN 0953-7104
    DOI 10.1080/09537104.2024.2313359
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development.

    Friebe, Andreas / Sandner, Peter / Schmidtko, Achim

    Naunyn-Schmiedeberg's archives of pharmacology

    2019  Volume 393, Issue 2, Page(s) 287–302

    Abstract: Cyclic guanosine monophosphate (cGMP) is a unique second messenger molecule formed in different cell types and tissues. cGMP targets a variety of downstream effector molecules and, thus, elicits a very broad variety of cellular effects. Its production is ...

    Abstract Cyclic guanosine monophosphate (cGMP) is a unique second messenger molecule formed in different cell types and tissues. cGMP targets a variety of downstream effector molecules and, thus, elicits a very broad variety of cellular effects. Its production is triggered by stimulation of either soluble guanylyl cyclase (sGC) or particulate guanylyl cyclase (pGC); both enzymes exist in different isoforms. cGMP-induced effects are regulated by endogenous receptor ligands such as nitric oxide (NO) and natriuretic peptides (NPs). Depending on the distribution of sGC and pGC and the formation of ligands, this pathway regulates not only the cardiovascular system but also the kidney, lung, liver, and brain function; in addition, the cGMP pathway is involved in the pathogenesis of fibrosis, inflammation, or neurodegeneration and may also play a role in infectious diseases such as malaria. Moreover, new pharmacological approaches are being developed which target sGC- and pGC-dependent pathways for the treatment of various diseases. Therefore, it is of key interest to understand this pathway from scratch, beginning with the molecular basis of cGMP generation, the structure and function of both guanylyl cyclases and cGMP downstream targets; research efforts also focus on the subsequent signaling cascades, their potential crosstalk, and also the translational and, ultimately, the clinical implications of cGMP modulation. This review tries to summarize the contributions to the "9th International cGMP Conference on cGMP Generators, Effectors and Therapeutic Implications" held in Mainz in 2019. Presented data will be discussed and extended also in light of recent landmark findings and ongoing activities in the field of preclinical and clinical cGMP research.
    MeSH term(s) Animals ; Cyclic GMP/chemistry ; Cyclic GMP/metabolism ; Humans ; Signal Transduction
    Chemical Substances Cyclic GMP (H2D2X058MU)
    Language English
    Publishing date 2019-12-18
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 121471-8
    ISSN 1432-1912 ; 0028-1298
    ISSN (online) 1432-1912
    ISSN 0028-1298
    DOI 10.1007/s00210-019-01779-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Book ; Online ; Thesis: Die nitrerge Neurotransmission im Gastrointestinaltrakt der Maus

    Beck, Katharina [Verfasser] / Friebe, Andreas [Gutachter]

    2019  

    Author's details Katharina Beck ; Gutachter: Andreas Friebe
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Universität Würzburg
    Publishing place Würzburg
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

To top